Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Acute Lung Injury

ClinicalTrials.gov lists 390 trials for Acute Lung Injury or a narrower condition beneath it.

MeSH D055371 Respiratory Tract Diseases C08 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 22 Phase 1/2 Phase 1/2 16 Phase 2 Phase 2 52 Phase 2/3 Phase 2/3 11 Phase 3 Phase 3 23 Phase 4 Phase 4 12 Not applicable Not applicable 111 Observational Observational 140 Phase 1 Phase 1 22 Phase 1/2 Phase 1/2 16 Phase 2 Phase 2 52 Phase 2/3 Phase 2/3 11 Phase 3 Phase 3 23 Phase 4 Phase 4 12 Not applicable Not applicable 111 Observational Observational 140

Trials per phase

1 more section with rows

380 of the 390 trials are tagged with Acute Lung Injury itself; the rest are tagged with a narrower condition beneath it.

Get the Acute Lung Injury report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Acute Lung Injury trials start? (27)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 41

1999: 1 trials (Phase 2 1) 2001: 6 trials (Observational 2, Not applicable 1, Phase 3 1, Phase 1/2 2) 2002: 2 trials (Observational 1, Not applicable 1) 2003: 2 trials (Phase 3 1, Phase 2 1) 2004: 11 trials (Observational 3, Not applicable 3, Phase 4 1, Phase 3 1, Phase 2 1, Phase 1 2) 2005: 4 trials (Observational 2, Not applicable 2) 2006: 6 trials (Observational 1, Not applicable 1, Phase 2/3 1, Phase 2 2, Phase 1 1) 2007: 14 trials (Observational 5, Not applicable 5, Phase 3 2, Phase 2/3 1, Phase 2 1) 2008: 17 trials (Observational 8, Not applicable 4, Phase 4 1, Phase 2/3 2, Phase 2 2) 2009: 20 trials (Observational 7, Not applicable 8, Phase 4 1, Phase 3 1, Phase 2 2, Phase 1/2 1) 2010: 21 trials (Observational 6, Not applicable 8, Phase 3 3, Phase 2/3 1, Phase 2 2, Phase 1/2 1) 2011: 26 trials (Observational 13, Not applicable 3, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 4, Phase 1 3) 2012: 18 trials (Observational 3, Not applicable 4, Phase 3 3, Phase 2 5, Phase 1 3) 2013: 11 trials (Observational 2, Not applicable 4, Phase 3 1, Phase 1/2 1, Phase 1 3) 2014: 9 trials (Observational 3, Not applicable 2, Phase 2 2, Phase 1/2 1, Phase 1 1) 2015: 7 trials (Observational 2, Not applicable 3, Phase 2 1, Phase 1/2 1) 2016: 9 trials (Observational 4, Not applicable 2, Phase 3 1, Phase 2 1, Phase 1/2 1) 2017: 11 trials (Observational 6, Not applicable 4, Phase 1 1) 2018: 10 trials (Observational 3, Not applicable 5, Phase 4 1, Phase 2 1) 2019: 13 trials (Observational 6, Not applicable 3, Phase 4 2, Phase 2 1, Phase 1/2 1) 2020: 41 trials (Observational 12, Not applicable 6, Phase 4 2, Phase 3 4, Phase 2/3 2, Phase 2 8, Phase 1/2 5, Phase 1 2) 2021: 20 trials (Observational 4, Not applicable 6, Phase 3 1, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 3) 2022: 17 trials (Observational 5, Not applicable 8, Phase 4 1, Phase 2 2, Phase 1 1) 2023: 15 trials (Observational 6, Not applicable 6, Phase 3 1, Phase 2 2) 2024: 22 trials (Observational 17, Not applicable 5) 2025: 21 trials (Observational 7, Not applicable 6, Phase 4 1, Phase 2/3 1, Phase 2 6)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 28
2025 21
2024 22
2023 15
2022 17
2021 20
2020 41
2019 13
2018 10
2017 11

Showing 10 of 27 earlier years.

Start your 14-day trial Email me all 27 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 33 trials starting in 2026 and about 28 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 26 trials still running at the 2026-10-09 snapshot; registered median of 18 months across 238 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Acute Lung Injury trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 22
Phase 1/2 16
Phase 2 52
Phase 2/3 11
Phase 3 23
Phase 4 12
Not applicable 111
Observational 140
Expanded access 3

How many Acute Lung Injury trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 23
Recruiting 42
Enrolling by invitation 2
Active, not recruiting 3
Completed 200

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Acute Lung Injury trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
GlaxoSmithKline 5
National Heart, Lung, and Blood Institute (NHLBI) 5
PPD Development, LP 4

Which drugs are being tested for Acute Lung Injury? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Vitamin C 6
METHYLPREDNISOLONE 4
DEXMEDETOMIDINE 3
Sivelestat 3
(LMW)heparin 3

Interventions as named in the registry (10)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
mechanical ventilation (MV) 7
Medicinal gas - oxygen (Nippon Gases 200 bar) 3
EC Aspirin 2
Cohort B: paridiprubart 2
TD-0903 2

Showing 5 of 10 interventions.

Start your 14-day trial Email me all 10 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Acute Lung Injury trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Respiratory failure 74 11
Death 64 6
COVID-19 36 5
Acute respiratory distress syndrome 35 9
Sepsis 32 8

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Acute Lung Injury? (387)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Humanized Citrullinated Histone H3 Monoclonal Antibody Improves Respiratory Function and Attenuates Neutrophil-Mediated Inflammation in a Rodent Model of Smoke Inhalation Lung Injury. Journal of the American College of Surgeons 2026 Yes
High Respiratory and Cardiac Drive Exacerbate Secondary Lung Injury in Patients With Critical Illness. Journal of intensive care medicine 2025 Yes
Serum Exosomal miR-216a Contributes to Acute Pancreatitis-Associated Acute Lung Injury by Enhancing Endothelial Cell Vascular Permeability Through Downregulating LAMC1. Pancreas 2025 Yes
Lifei Qingchang Tang attenuates acute lung injury <i>via</i> the NF-κB and MAPK signaling pathways. Journal of Asian natural products research 2025 Yes
Comparison of 16 Pediatric Acute Respiratory Distress Syndrome-Associated Plasma Biomarkers With Changing Lung Injury Severity. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 2024 Yes

Showing 5 of 387 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (12)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Acute lung injury Annual incidence 6-9 / 10 000 United States US Exact
Acute lung injury Annual incidence 6-9 / 10 000 United States US Exact
Acute lung injury Annual incidence 6-9 / 10 000 United States US Unspecified
Acute lung injury Annual incidence 1-5 / 10 000 Australia Not stated Exact
Acute lung injury Point prevalence 1-5 / 10 000 Europe Not stated Exact

Showing 5 of 12 prevalence observations.

Start your 14-day trial Email me all 12 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Acute lung injury 178320 Exact Orphadata Science knowledge files, Product 1
Acute lung injury 178320 Exact Orphanet Rare Disease Ontology (ORDO)

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages